{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:59:13Z","timestamp":1788260353467,"version":"build-2803163510"},"reference-count":56,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Idiopathic inflammatory myopathies (IIMs) comprise a spectrum of autoinflammatory disease characterized primarily by muscle inflammation, with secondary involvement of diverse organs including joints, skin, lungs, heart, and the gastrointestinal system. Managing these conditions poses considerable challenges, often inflicting profound distress on the afflicted individuals. Encouragingly, the deployment of chimeric antigen receptor (CAR) T cell therapy has demonstrated promising efficacy across various autoimmune diseases, extending hope for ameliorating the burden of IIM. This review provides an overview of the role of B cells in IIM pathogenesis, currently available B cell\u2013depleting therapies, reasons for their lack of efficacy, and the application of CD19 CAR T cell therapy in the management of IIM, encompassing indications, efficacy, and tolerability profiles in these patient populations. Through this comprehensive review, we propose clinical trial design, target population, response criteria, and long-term follow-up measures for future clinical trials focusing on CD19 CAR T cell therapy in IIM. This overview aims to streamline research efforts and enhance the efficacy of therapeutic interventions in challenging cases.<\/jats:p>","DOI":"10.3899\/jrheum.2024-1115","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T08:25:13Z","timestamp":1742027113000},"page":"532-542","source":"Crossref","is-referenced-by-count":7,"title":["Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-0215","authenticated-orcid":false,"given":"Anushka","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1940-3064","authenticated-orcid":false,"given":"Maha","family":"Almackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2025110503550824000_52.6.532.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev444"},{"key":"2025110503550824000_52.6.532.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124958"},{"key":"2025110503550824000_52.6.532.3","doi-asserted-by":"publisher","DOI":"10.2174\/187153006779025775"},{"key":"2025110503550824000_52.6.532.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1164-z"},{"key":"2025110503550824000_52.6.532.5","first-page":"463","article-title":"Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets","volume":"19","author":"Lahouti","year":"2015","journal-title":"Discov Med"},{"key":"2025110503550824000_52.6.532.6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01372"},{"key":"2025110503550824000_52.6.532.7","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12451"},{"key":"2025110503550824000_52.6.532.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.04.006"},{"key":"2025110503550824000_52.6.532.9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177721"},{"key":"2025110503550824000_52.6.532.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120555"},{"key":"2025110503550824000_52.6.532.11","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0454-8"},{"key":"2025110503550824000_52.6.532.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2025110503550824000_52.6.532.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew146"},{"key":"2025110503550824000_52.6.532.14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609"},{"key":"2025110503550824000_52.6.532.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8408-9"},{"key":"2025110503550824000_52.6.532.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.38270"},{"key":"2025110503550824000_52.6.532.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225773"},{"key":"2025110503550824000_52.6.532.18","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"2025110503550824000_52.6.532.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202861"},{"key":"2025110503550824000_52.6.532.20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2572"},{"key":"2025110503550824000_52.6.532.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24411"},{"key":"2025110503550824000_52.6.532.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.41075"},{"key":"2025110503550824000_52.6.532.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key428"},{"key":"2025110503550824000_52.6.532.24","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220"},{"key":"2025110503550824000_52.6.532.25","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-017-0100-y"},{"key":"2025110503550824000_52.6.532.26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169"},{"key":"2025110503550824000_52.6.532.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408786"},{"key":"2025110503550824000_52.6.532.28","first-page":"11","article-title":"Cytotoxic T cell hybridomas: generation and characterization","volume":"100","author":"Eshhar","year":"1982","journal-title":"Curr Top Microbiol Immunol"},{"key":"2025110503550824000_52.6.532.29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"2025110503550824000_52.6.532.30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0186"},{"key":"2025110503550824000_52.6.532.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021"},{"key":"2025110503550824000_52.6.532.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125423"},{"key":"2025110503550824000_52.6.532.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009"},{"key":"2025110503550824000_52.6.532.34","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430"},{"key":"2025110503550824000_52.6.532.35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"2025110503550824000_52.6.532.36","first-page":"e65291","article-title":"Current strategies to improve Chimeric Antigen Receptor T (CAR-T) cell persistence","volume":"16","author":"Ghorai","year":"2024","journal-title":"Cureus"},{"key":"2025110503550824000_52.6.532.37","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697"},{"key":"2025110503550824000_52.6.532.38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910511"},{"key":"2025110503550824000_52.6.532.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2025110503550824000_52.6.532.40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00023-5"},{"key":"2025110503550824000_52.6.532.41","unstructured":"Taubmann J , Knitza J , M\u00fcller F , . Efficacy and safety of Car-T-cell treatment in refractory antisynthetase syndrome \u2013 data of the first three patients [abstract]. Arthritis Rheumatol Suppl 2023;75 Suppl 9."},{"key":"2025110503550824000_52.6.532.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025110503550824000_52.6.532.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121"},{"key":"2025110503550824000_52.6.532.44","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025110503550824000_52.6.532.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753"},{"key":"2025110503550824000_52.6.532.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142"},{"key":"2025110503550824000_52.6.532.47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663"},{"key":"2025110503550824000_52.6.532.48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002907"},{"key":"2025110503550824000_52.6.532.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0215-7"},{"key":"2025110503550824000_52.6.532.50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196124"},{"key":"2025110503550824000_52.6.532.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"2025110503550824000_52.6.532.52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1368"},{"key":"2025110503550824000_52.6.532.53","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017"},{"key":"2025110503550824000_52.6.532.54","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"2025110503550824000_52.6.532.55","unstructured":"US Food and Drug Administration (FDA) . FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell Immunotherapies [Internet. Accessed February 7, 2025]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous"},{"key":"2025110503550824000_52.6.532.56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.1011"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:55:22Z","timestamp":1762343722000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.3899\/jrheum.2024-1115"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1115","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]}}}